Browsing by Author "Trimboli, Rubina M."

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Image-guided breast biopsy and localisation: recommendations for information to women and referring physicians by the European Society of Breast Imaging
    (SPRINGEROPEN, 2020-01-01) Bick, Ulrich; Trimboli, Rubina M.; Athanasiou, Alexandra; Balleyguier, Corinne; Baltzer, Pascal A. T.; Bernathova, Maria; Borbely, Krisztina; Brkljacic, Boris; Carbonaro, Luca A.; Clauser, Paola; Cassano, Enrico; Colin, Catherine; Esen, Gul; Evans, Andrew; Fallenberg, Eva M.; Fuchsjaeger, Michael H.; Gilbert, Fiona J.; Helbich, Thomas H.; Heywang-Koebrunner, Sylvia H.; Herranz, Michel; Kinkel, Karen; Kilburn-Toppin, Fleur; Kuhl, Christiane K.; Lesaru, Mihai; Lobbes, Marc B. I.; Mann, Ritse M.; Martincich, Laura; Panizza, Pietro; Pediconi, Federica; Pijnappel, Ruud M.; Pinker, Katja; Schiaffino, Simone; Sella, Tamar; Thomassin-Naggara, Isabelle; Tardivon, Anne; Van Ongeval, Chantal; Wallis, Matthew G.; Zackrisson, Sophia; Forrai, Gabor; Herrero, Julia Camps; Sardanelli, Francesco; EUSOBI, European Soc Breast Imaging
    We summarise here the information to be provided to women and referring physicians about percutaneous breast biopsy and lesion localisation under imaging guidance. After explaining why a preoperative diagnosis with a percutaneous biopsy is preferred to surgical biopsy, we illustrate the criteria used by radiologists for choosing the most appropriate combination of device type for sampling and imaging technique for guidance. Then, we describe the commonly used devices, from fine-needle sampling to tissue biopsy with larger needles, namely core needle biopsy and vacuum-assisted biopsy, and how mammography, digital breast tomosynthesis, ultrasound, or magnetic resonance imaging work for targeting the lesion for sampling or localisation. The differences among the techniques available for localisation (carbon marking, metallic wire, radiotracer injection, radioactive seed, and magnetic seed localisation) are illustrated. Type and rate of possible complications are described and the issue of concomitant antiplatelet or anticoagulant therapy is also addressed. The importance of pathological-radiological correlation is highlighted: when evaluating the results of any needle sampling, the radiologist must check the concordance between the cytology/pathology report of the sample and the radiological appearance of the biopsied lesion. We recommend that special attention is paid to a proper and tactful approach when communicating to the woman the need for tissue sampling as well as the possibility of cancer diagnosis, repeat tissue sampling, and or even surgery when tissue sampling shows a lesion with uncertain malignant potential (also referred to as ``high-risk{''} or B3 lesions). Finally, seven frequently asked questions are answered.
  • Thumbnail Image
    Item
    Magnetic resonance imaging before breast cancer surgery: results of an observational multicenter international prospective analysis (MIPA)
    (SPRINGER, 2022-01-01) Sardanelli, Francesco; Trimboli, Rubina M.; Houssami, Nehmat; Gilbert, Fiona J.; Helbich, Thomas H.; Alvarez Benito, Marina; Balleyguier, Corinne; Bazzocchi, Massimo; Bult, Peter; Calabrese, Massimo; Camps Herrero, Julia; Cartia, Francesco; Cassano, Enrico; Clauser, Paola; Cozzi, Andrea; de Andrade, Danubia A.; de Lima Docema, Marcos F.; Depretto, Catherine; Dominelli, Valeria; Forrai, Gabor; Girometti, Rossano; Harms, Steven E.; Hilborne, Sarah; Ienzi, Raffaele; Lobbes I, Marc B.; Losio, Claudio; Mann, Ritse M.; Montemezzi, Stefania; Obdeijn, Inge-Marie; Ozcan, Umit A.; Pediconi, Federica; Pinker, Katja; Preibsch, Heike; Raya Povedano, Jose L.; Sacchetto, Daniela; Scaperrotta, Gianfranco P.; Schiaffino, Simone; Schlooz, Margrethe; Szabo, Botond K.; Taylor, Donna B.; Ulus, Ozden S.; Van Goethem, Mireille; Veltman, Jeroen; Weigel, Stefanie; Wenkel, Evelyn; Zuiani, Chiara; Di Leo, Giovanni
    Objectives Preoperative breast magnetic resonance imaging (MRI) can inform surgical planning but might cause overtreatment by increasing the mastectomy rate. The Multicenter International Prospective Analysis (MIPA) study investigated this controversial issue. Methods This observational study enrolled women aged 18-80 years with biopsy-proven breast cancer, who underwent MRI in addition to conventional imaging (mammography and/or breast ultrasonography) or conventional imaging alone before surgery as routine practice at 27 centers. Exclusion criteria included planned neoadjuvant therapy, pregnancy, personal history of any cancer, and distant metastases. Results Of 5896 analyzed patients, 2763 (46.9\%) had conventional imaging only (noMRI group), and 3133 (53.1\%) underwent MRI that was performed for diagnosis, screening, or unknown purposes in 692/3133 women (22.1\%), with preoperative intent in 2441/3133 women (77.9\%, MRI group). Patients in the MRI group were younger, had denser breasts, more cancers >= 20 mm, and a higher rate of invasive lobular histology than patients who underwent conventional imaging alone (p < 0.001 for all comparisons). Mastectomy was planned based on conventional imaging in 22.4\% (MRI group) versus 14.4\% (noMRI group) (p < 0.001). The additional planned mastectomy rate in the MRI group was 11.3\%. The overall performed first- plus second-line mastectomy rate was 36.3\% (MRI group) versus 18.0\% (noMRI group) (p < 0.001). In women receiving conserving surgery, MRI group had a significantly lower reoperation rate (8.5\% versus 11.7\%, p < 0.001). Conclusions Clinicians requested breast MRI for women with a higher a priori probability of receiving mastectomy. MRI was associated with 11.3\% more mastectomies, and with 3.2\% fewer reoperations in the breast conservation subgroup.
  • Thumbnail Image
    Item
    Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey
    (SPRINGER, 2017-01-01) Sardanelli, Francesco; Aase, Hildegunn S.; Alvarez, Marina; Azavedo, Edward; Baarslag, Henk J.; Balleyguier, Corinne; Baltzer, Pascal A.; Beslagic, Vanesa; Bick, Ulrich; Bogdanovic-Stojanovic, Dragana; Briediene, Ruta; Brkljacic, Boris; Herrero, Julia Camps; Colin, Catherine; Cornford, Eleanor; Danes, Jan; de Geer, Gerard; Esen, Gul; Evans, Andrew; Fuchsjaeger, Michael H.; Gilbert, Fiona J.; Graf, Oswald; Hargaden, Gormlaith; Helbich, Thomas H.; Heywang-Koebrunner, Sylvia H.; Ivanov, Valentin; Jonsson, Asbjorn; Kuhl, Christiane K.; Lisencu, Eugenia C.; Luczynska, Elzbieta; Mann, Ritse M.; Marques, Jose C.; Martincich, Laura; Mortier, Margarete; Mueller-Schimpfle, Markus; Ormandi, Katalin; Panizza, Pietro; Pediconi, Federica; Pijnappel, Ruud M.; Pinker, Katja; Rissanen, Tarja; Rotaru, Natalia; Saguatti, Gianni; Sella, Tamar; Slobodnikova, Jana; Talk, Maret; Taourel, Patrice; Trimboli, Rubina M.; Vejborg, Ilse; Vourtsis, Athina; Forrai, Gabor
    EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 \% for women aged 50-69 years taking up the invitation while the probability of false-positive needle biopsy is < 1 \% per round and overdiagnosis is only 1-10 \% for a 20-year screening. Mortality reduction was also observed for the age groups 40-49 years and 70-74 years, although with ``limited evidence{''}. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50-69 years
  • Thumbnail Image
    Item
    Solving the preoperative breast MRI conundrum: design and protocol of the MIPA study
    (SPRINGER, 2020-01-01) Sardanelli, Francesco; Trimboli, Rubina M.; Houssami, Nehmat; Gilbert, Fiona J.; Helbich, Thomas H.; Alvarez Benito, Marina; Balleyguier, Corinne; Bazzocchi, Massimo; Bult, Peter; Calabrese, Massimo; Camps Herrero, Julia; Cartia, Francesco; Cassano, Enrico; Clauser, Paola; de Andrade, Danubia A.; de Lima Docema, Marcos F.; Depretto, Catherine; Forrai, Gabor; Girometti, Rossano; Harms, Steven E.; Hilborne, Sarah; Ienzi, Raffaele; Lobbes, Marc B. I.; Losio, Claudio; Mann, Ritse M.; Montemezzi, Stefania; Obdeijn, Inge-Marie; Ozcan, Umit Aksoy; Pediconi, Federica; Preibsch, Heike; Raya-Povedano, Jose L.; Sacchetto, Daniela; Scaperrotta, Gianfranco P.; Schlooz, Margrethe; Szabo, Botond K.; Ulus, Ozden S.; Taylor, Donna B.; Van Goethem, Mireille; Veltman, Jeroen; Weigel, Stefanie; Wenkel, Evelyn; Zuiani, Chiara; Di Leo, Giovanni
    Despite its high diagnostic performance, the use of breast MRI in the preoperative setting is controversial. It has the potential for personalized surgical management in breast cancer patients, but two of three randomized controlled trials did not show results in favor of its introduction for assessing the disease extent before surgery. Meta-analyses showed a higher mastectomy rate in women undergoing preoperative MRI compared to those who do not. Nevertheless, preoperative breast MRI is increasingly used and a survey from the American Society of Breast Surgeons showed that 41\% of respondents ask for it in daily practice. In this context, a large-scale observational multicenter international prospective analysis (MIPA study) was proposed under the guidance of the European Network for the Assessment of Imaging in Medicine (EuroAIM). The aims were (1) to prospectively and systematically collect data on consecutive women with a newly diagnosed breast cancer, not candidates for neoadjuvant therapy, who are offered or not offered breast MRI before surgery according to local practice